Sarepta Therapeutics Business Model Canvas

Design and optimization of RNA-targeted, gene therapy and gene editing programs drive Sarepta’s pipeline expansion, building on three FDA-approved DMD therapies to date. Rigorous preclinical efficacy and safety studies de-risk candidates ahead of INDs and clinical entry. Biomarker development (including dystrophin quantification assays) underpins precise patient selection. Continuous IP filing strategy secures platform advances and freedom to operate.

Phase 1–4 trials validate safety, efficacy and durability across diverse DMD subpopulations, enrolling cohorts from dozens to hundreds per study; DMD affects ~1 in 3,500–5,000 male births. Natural history and registry studies spanning 50+ countries inform endpoints and comparator baselines. Real-world evidence underpins label expansions and payer decisions while long-term follow-up monitors evolving benefit‑risk profiles.

Proprietary oligonucleotide chemistry, engineered AAV capsids and editing tools drive differentiated efficacy and safety across Sarepta’s neuromuscular and gene-editing programs, underpinning clinical progress in 2024. Patents and trade secrets — a global IP estate of >1,000 issued and pending filings — protect core assets and market exclusivity. Freedom-to-operate analyses guide pipeline prioritization, while selective licensing deals and collaborations augment capabilities and address gaps in 2024 strategic planning.

Process and analytical expertise in gene therapy and RNA medicines enable scalable manufacturing with QC/QA systems aligned to FDA and EMA standards as of 2024. Strategic capacity, via in-house plants and external CDMOs across North America and Europe, secures commercial supply. Cold-chain and cryo logistics (−80°C to liquid nitrogen vapor temps) preserve product integrity.

Therapies target the genetic root cause for defined DMD subtypes, with Sarepta holding approved exon-skipping drugs (eteplirsen, golodirsen, casimersen) for specific mutations. Tailored approaches aim for meaningful functional gains measured by dystrophin restoration and 6MWT changes. Companion biomarkers (dystrophin by biopsy, molecular assays) guide patient selection and monitoring. Mutation specificity (exon 51 ~13%, exon 53 ~8% of DMD) minimizes unnecessary exposure.

Gene therapy and RNA approaches at Sarepta aim for sustained expression or restoration, exemplified by FDA approval of Elevidys in 2023 and ongoing long-term follow-up studies to support durability claims. Long-term monitoring programs continue to assess multi-year persistence and safety. Early intervention in Duchenne patients may slow functional decline. Durable outcomes can translate to improved quality of life and reduced lifetime care needs.

Focused relationships with neuromuscular neurologists and pediatric specialists drive adoption in a disease affecting roughly 1 in 3,500–5,000 male births, concentrating care at specialist centers. Field teams deliver clinical resources and case support to accelerate appropriate use and reimbursement. Ongoing education updates clinicians as evidence evolves, while advisory boards (regularly convened) identify and close practice gaps.

Integrated COE partnerships deliver coordinated dosing, monitoring, and safety workflows that deepen institutional loyalty and reduce administration errors. Site enablement programs accelerate referrals and patient throughput by streamlining scheduling and payer navigation. Secure data-sharing with COEs supports quality initiatives and outcomes tracking across sites. Joint protocols standardize care pathways, improving consistency and measurable treatment adherence.

Targeted coverage prioritizes high-volume DMD treatment centers where Sarepta's four FDA-approved DMD therapies are concentrated, improving access for the majority of eligible patients. Dedicated account managers coordinate ordering, infusion scheduling and logistics with hospital pharmacies to reduce turnaround times. Service-level agreements set delivery and cold-chain reliability standards. Real-time clinic feedback is used to refine forecasting and supply allocations.

Specialty pharmacy networks coordinate benefits, prior authorizations, shipping and adherence support for Sarepta therapies, including hub services and nurse case managers. Cold-chain integrity is monitored end-to-end with real-time telemetry and chain-of-custody tracking. Data feeds into registries and EMRs to enable outcomes and adherence tracking, and broad payer coverage—specialty drugs made up over half of US drug spend in 2024—improves patient access.

DMD patients and caregivers—primary beneficiaries—seek treatments that slow progression and improve function; DMD affects about 1 in 3,500–5,000 male births. Families require education, financial aid and logistical support for high-cost therapies and multidisciplinary care. Early diagnosis via newborn screening increases eligibility and improves outcomes. Community trust drives engagement and adherence.

Neuromuscular specialists and pediatric HCPs demand robust clinical evidence and clear protocols, exemplified by Sarepta’s Elevidys FDA approval in June 2023 which relied on dystrophin restoration as a key biomarker. Access to genetic testing and validated biomarkers (dystrophin, CK) guides patient selection. Ongoing support programs and remote monitoring facilitate safety follow‑up and outcomes tracking. Key opinion leaders drive guideline uptake and community adoption.

Discovery, vector engineering and oligonucleotide optimization drive high upfront capital requirements for Sarepta, with specialized platforms and GMP-grade production increasing per-project costs. Complex in vitro assays, multiple animal models and advanced analytics lengthen timelines and raise incremental spend. Patent prosecution, freedom-to-operate analyses and licensing add legal and deal-related expenses. Active portfolio triage reallocates resources to programs with the strongest risk-adjusted return potential.

Multicenter DMD trials drive high per-patient costs—serial MRIs (~1,000–3,000 per scan) and biomarker assays (~500–2,000) plus imaging core lab fees often push per-patient costs into the low- to mid-six figures; pediatric oversight and intensive safety monitoring add ongoing staffing and DSMB expenses. Registries and post-marketing studies continue after approval, while site startup and recruitment support (site set-up ~50–150k, recruitment ~$10–50k/patient) require sustained funding.

Revenue from approved exon-skipping therapies (eteplirsen 2016, golodirsen 2019, casimersen 2021) and gene therapy Elevidys (SRP-9001, FDA 2023) drives Sarepta’s DMD top line. Uptake depends on the eligible population (DMD prevalence ~1 in 3,500–5,000 male births) and infusion/administration center capacity. International expansion into EU/Japan markets expands addressable patients. Adherence and persistence to long‑term regimens sustain recurring revenue.

New country launches unlock additional markets given Duchenne muscular dystrophy prevalence of ~1 in 3,500–5,000 male births, expanding addressable patients; label extensions into broader indications materially increase eligible cohorts; pediatric-to-adult transition programs support lifetime treatment continuity and retention; pricing and access strategies are calibrated to local HTA norms (eg, NICE ~£20,000–30,000/QALY) to optimize reimbursement.